search
Back to results

A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
SLV337
SLV337
SLV337
Sponsored by
Abbott Products
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring type 2 diabetes, interventional, placebo, controlled, PK, PD, safety

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers
Inclusion Criteria Type 2 diabetes ,stable dose of Metformin,HbA1c >= 7%, but < 9% Exclusion Criteria Type 1 diabetes mellitus, Body Mass Index (BMI) >40.0 kg/m2, evidence of unstable cardiovascular diseases, NYHA class I to IV, ALT > 1.5 times UNL, creatinine clearance <60 mL/min

Sites / Locations

  • Site Reference ID/Investigator# 54183
  • Site Reference ID/Investigator# 54182
  • Site Reference ID/Investigator# 44722
  • Site Reference ID/Investigator# 44723
  • Site Reference ID/Investigator# 44725
  • Site Reference ID/Investigator# 44724
  • Site Reference ID/Investigator# 54185
  • Site Reference ID/Investigator# 44727
  • Site Reference ID/Investigator# 54184
  • Site Reference ID/Investigator# 44728
  • Site Reference ID/Investigator# 44730
  • Site Reference ID/Investigator# 44729

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

1

2

3

4

Arm Description

Outcomes

Primary Outcome Measures

Change from Baseline in alanine amino transferase level to Day 35
Change from baseline in Creatinine level to Day 35
Change from baseline in the count of Red blood cells to Day 35
Change from baseline in White blood cells count to Day 35
Change from baseline in Creatinine kinase level to Day 35

Secondary Outcome Measures

Change from baseline in Fasting plasma glucose level to Day 28
Change from baseline in Adiponectin level to Day 28
Change from baseline in Triglycerides level to Day 28
Change from baseline in High density lipoprotein cholesterol level to Day 28

Full Information

First Posted
June 18, 2009
Last Updated
December 30, 2011
Sponsor
Abbott Products
Collaborators
Quintiles, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00924534
Brief Title
A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes
Official Title
A Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV337 in Patients With Type 2 Diabetes on Metformin Monotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
December 2009 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Products
Collaborators
Quintiles, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
type 2 diabetes, interventional, placebo, controlled, PK, PD, safety

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Placebo Comparator
Arm Title
2
Arm Type
Experimental
Arm Title
3
Arm Type
Experimental
Arm Title
4
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Intervention Type
Drug
Intervention Name(s)
SLV337
Intervention Description
SLV337 400 mg/day
Intervention Type
Drug
Intervention Name(s)
SLV337
Intervention Description
SLV337 800 mg/day
Intervention Type
Drug
Intervention Name(s)
SLV337
Intervention Description
SLV337 1400 mg/day
Primary Outcome Measure Information:
Title
Change from Baseline in alanine amino transferase level to Day 35
Time Frame
35 days
Title
Change from baseline in Creatinine level to Day 35
Time Frame
35 days
Title
Change from baseline in the count of Red blood cells to Day 35
Time Frame
35 days
Title
Change from baseline in White blood cells count to Day 35
Time Frame
35 days
Title
Change from baseline in Creatinine kinase level to Day 35
Time Frame
35 days
Secondary Outcome Measure Information:
Title
Change from baseline in Fasting plasma glucose level to Day 28
Time Frame
28 days
Title
Change from baseline in Adiponectin level to Day 28
Time Frame
28 days
Title
Change from baseline in Triglycerides level to Day 28
Time Frame
28 days
Title
Change from baseline in High density lipoprotein cholesterol level to Day 28
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Type 2 diabetes ,stable dose of Metformin,HbA1c >= 7%, but < 9% Exclusion Criteria Type 1 diabetes mellitus, Body Mass Index (BMI) >40.0 kg/m2, evidence of unstable cardiovascular diseases, NYHA class I to IV, ALT > 1.5 times UNL, creatinine clearance <60 mL/min
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francis Roy, MS
Organizational Affiliation
Abbott Products
Official's Role
Study Director
Facility Information:
Facility Name
Site Reference ID/Investigator# 54183
City
Dimitrovgrad
ZIP/Postal Code
6400
Country
Bulgaria
Facility Name
Site Reference ID/Investigator# 54182
City
Pleven
ZIP/Postal Code
5800
Country
Bulgaria
Facility Name
Site Reference ID/Investigator# 44722
City
Plovdiv
ZIP/Postal Code
4000
Country
Bulgaria
Facility Name
Site Reference ID/Investigator# 44723
City
Sofia
ZIP/Postal Code
1407
Country
Bulgaria
Facility Name
Site Reference ID/Investigator# 44725
City
Lubin
ZIP/Postal Code
59-301
Country
Poland
Facility Name
Site Reference ID/Investigator# 44724
City
Pulawy
ZIP/Postal Code
24-100
Country
Poland
Facility Name
Site Reference ID/Investigator# 54185
City
Radzymin
ZIP/Postal Code
05-250
Country
Poland
Facility Name
Site Reference ID/Investigator# 44727
City
Ruda Slaska
Country
Poland
Facility Name
Site Reference ID/Investigator# 54184
City
Wroclaw
ZIP/Postal Code
50-349
Country
Poland
Facility Name
Site Reference ID/Investigator# 44728
City
Cape Town
ZIP/Postal Code
7130
Country
South Africa
Facility Name
Site Reference ID/Investigator# 44730
City
Cape Town
ZIP/Postal Code
7937
Country
South Africa
Facility Name
Site Reference ID/Investigator# 44729
City
Johannesburg
ZIP/Postal Code
2198
Country
South Africa

12. IPD Sharing Statement

Learn more about this trial

A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs